Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,206 signal articles · 255 in last 24h · 114,915 total before filter · latest 1h ago
255last 24h
1849last 7d
299● bullish (7d)
167● bearish (7d)
205publishers
AllMacro321Earnings898M&A101Regulatory23Product17Analyst23
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
DraftKings Q1 Earnings Call Highlights
MarketBeat98d agoneutral
DraftKings Q1 Earnings Call Highlights

DraftKings (NASDAQ:DKNG) reported first-quarter 2026 results that exceeded management’s expectations, driven by continued strength in its core Sportsbook business and an increasing push into sports predictions. First-quarter results and updated cadence commentary Co-founder and CEO Jason Robins sai

What CoreWeave's Q1 earnings mean for Nvidia
Yahoo Finance Video98d agoneutralVIDEO
What CoreWeave's Q1 earnings mean for Nvidia

CoreWeave (CRWV) reported first quarter results on Thursday and missed Wall Street's guidance expectations. EMJ Capital founder and president Eric Jackson and Yahoo Finance Senior Business Reporter Ines Ferré chat with Yahoo Finance's Brian Sozzi about the earnings results and the outlook for Nvidia (NVDA) and artificial intelligence (AI) demand.

Investing.com98d agoneutral
Analysts cut Trade Desk ratings after weak Q2 guidance signals growth slowdown

Investing.com -- The Trade Desk was hit with downgrades from three Wall Street firms on Thursday after the digital advertising platform's second-quarter guidance came in below expectations, raising fears of a sustained deceleration in growth amid agency tensions, competitive pressures, and Middle East-related ad spending headwinds.

Gilead (GILD) Q1 2026 Earnings Call Transcript
Motley Fool98d agoneutral
Gilead (GILD) Q1 2026 Earnings Call Transcript

As we execute on the strongest pipeline in our history, Gilead Sciences, Inc. is also taking steps to further strengthen the company's position for the future. The ongoing success of the Esthugo launch is a key driver of this growth in HIV prevention, with first quarter sales growing 72% sequentially. Looking forward, with no major LOEs until 2036, Gilead Sciences, Inc.'s HIV business is poised for strong, durable growth supported by up to seven potential new HIV product launches by 2033.

Global equity funds draw inflows for the seventh week on earnings optimism
Reuters98d agoneutral
Global equity funds draw inflows for the seventh week on earnings optimism

May 8 () - Global equity funds attracted inflows for a seventh straight week in the period through May 6, supported ‌by upbeat first quarter earnings and hopes for a ‌U.35 billion of global equity funds during the week, ​though this was the smallest weekly inflow since March 18, LSEG Lipper data showed.